We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sigma-Aldrich Signs Exclusive Agreement with Rubicon Genomics to Commercialize Transplex™
News

Sigma-Aldrich Signs Exclusive Agreement with Rubicon Genomics to Commercialize Transplex™

Sigma-Aldrich Signs Exclusive Agreement with Rubicon Genomics to Commercialize Transplex™
News

Sigma-Aldrich Signs Exclusive Agreement with Rubicon Genomics to Commercialize Transplex™

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sigma-Aldrich Signs Exclusive Agreement with Rubicon Genomics to Commercialize Transplex™"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sigma-Aldrich has announced an exclusive licensing agreement with Rubicon Genomics to further develop and commercialize their TransPlex™ Whole Transcriptome Amplification (WTA) technology.

The TransPlex technology is a method which can be used for amplifying total RNA from a variety of sample sources such as animals, plants, and micro-organisms.

Under the terms of the agreement, Rubicon retains all rights to TransPlex™ for molecular diagnostics.

"We are excited to have this opportunity to expand our relationship with Rubicon," said Keith Jolliff, Director of Marketing for Genomics and Functional Genomics.

"Sigma-Aldrich is committed to bringing best-in-class- technologies to the genomic research community, and the TransPlex™ Whole Transcriptome Amplification kit is clearly in that category."

John Langmore, VP of Commercial Development at Rubicon, said: "Rubicon is very pleased that Sigma-Aldrich will be marketing TransPlex kits to complement the very successful GenomePlex® Whole Genome Amplification kits. We have confidence that their customers will embrace TransPlex for biological research and development of diagnostic products."

TransPlex WTA is designed to create a cDNA library from the isolated RNA template and to amplify the library in a single PCR reaction as the TransPlex reagents and protocols are optimized to ensure a linear representation of all expressed genes and exons that allow RNA samples to be amplified 1,000-10,000 fold in less than four hours.

This technology is made to work well even when the RNA is partially degraded, as in formalin-fixed paraffin-embedded tissue.

Advertisement